Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Ruxolitinib for Symptom Control in Patients with CLL
Lancet Haematol; ePub 2017 Jan 11; Jain, et al
Ruxolitinib was linked with significant improvements in disease-related symptoms and symptom interference scores in patients with chronic lymphocytic leukemia (CLL), according to a phase 2 trial involving 41 individuals.
Participants had CLL but did not require systemic therapy. They received 10 mg ruxolitinib orally twice daily. Investigators assessed patients before treatment and 3 months later using Scores on the Brief Fatigue Inventory (BFI), CLL module of the MD Anderson Symptom Inventory (MDASI), and symptom-associated interference in daily activities. Among the results:
- At 3 months, the average change from baseline in BFI score was 44.3%.
- Symptom interference score change was 43.4%.
- MDASI score change was 42.1%.
- 8 in every 10 patients experienced 20% or greater reduction in the average BFI.
- Most common adverse events were neutropenia, hypertension, insomnia, tinnitus and dizziness, and thrombocytopenia.
Jain P, Keating M, Renner S, et al. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: A single-group, phase 2 trial. [Published online ahead of print January 6, 2017]. Lancet Haematol. doi:10.1016/S2352-3026(16)30194-6.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al